-
1
-
-
17844402699
-
20-year outcomes following conservative management of clinically localized prostate cancer
-
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
-
(2005)
JAMA
, vol.293
, pp. 2095-2101
-
-
Albertsen, P.C.1
Hanley, J.A.2
Fine, J.3
-
2
-
-
79955705831
-
Radical prostatectomy versus watchful waiting in early prostate cancer
-
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer.N Engl J Med 2011; 364:1708-17.
-
(2011)
N Engl J Med
, vol.364
, pp. 1708-1717
-
-
Bill-Axelson, A.1
Holmberg, L.2
Ruutu, M.3
-
3
-
-
84859630507
-
Active surveillance in prostate cancer: Patient selection and triggers for intervention
-
Lees K, Durve M, Parker C. Active surveillance in prostate cancer: patient selection and triggers for intervention. Curr Opin Urol 2012; 22:210-5.
-
(2012)
Curr Opin Urol
, vol.22
, pp. 210-215
-
-
Lees, K.1
Durve, M.2
Parker, C.3
-
4
-
-
27344451557
-
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
-
Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
-
(2005)
Science
, vol.310
, pp. 644-648
-
-
Tomlins, S.A.1
Rhodes, D.R.2
Perner, S.3
-
5
-
-
34248510706
-
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
-
Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
-
(2007)
Oncogene
, vol.26
, pp. 4596-4599
-
-
Demichelis, F.1
Fall, K.2
Perner, S.3
-
6
-
-
84877097685
-
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: Results from a baseline analysis in the Canary Prostate Active Surveillance Study
-
Lin DW, Newcomb LF, Brown EC, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013;19:2442-50.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2442-2450
-
-
Lin, D.W.1
Newcomb, L.F.2
Brown, E.C.3
-
7
-
-
84895065530
-
Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer
-
Leyten GHJM, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42.
-
(2014)
Eur Urol
, vol.65
, pp. 534-542
-
-
Leyten, G.H.J.M.1
Hessels, D.2
Jannink, S.A.3
-
8
-
-
77954997528
-
Antibody-based detection of ERG rearrangement-positive prostate cancer
-
Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010;12: 590-8.
-
(2010)
Neoplasia
, vol.12
, pp. 590-598
-
-
Park, K.1
Tomlins, S.A.2
Mudaliar, K.M.3
-
9
-
-
84862080503
-
ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies
-
Braun M, Goltz D, Shaikhibrahim Z, et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis 2012;15:165-9.
-
(2012)
Prostate Cancer Prostatic Dis
, vol.15
, pp. 165-169
-
-
Braun, M.1
Goltz, D.2
Shaikhibrahim, Z.3
-
10
-
-
84856937557
-
Immunohistochemical pitfalls in prostate pathology
-
Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum Pathol 2012;43:313-24.
-
(2012)
Hum Pathol
, vol.43
, pp. 313-324
-
-
Brimo, F.1
Epstein, J.I.2
-
11
-
-
79959684555
-
The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies
-
Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 2011;35: 1062-8.
-
(2011)
Am J Surg Pathol
, vol.35
, pp. 1062-1068
-
-
Yaskiv, O.1
Zhang, X.2
Simmerman, K.3
-
12
-
-
84857781655
-
ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer
-
Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2012;25:471-9.
-
(2012)
Mod Pathol
, vol.25
, pp. 471-479
-
-
Hoogland, A.M.1
Jenster, G.2
Van Weerden, W.M.3
-
13
-
-
24144493035
-
The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma
-
Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
-
(2005)
Am J Surg Pathol
, vol.29
, pp. 1228-1242
-
-
Epstein, J.I.1
Allsbrook, W.C.2
Amin, M.B.3
Egevad, L.L.4
-
14
-
-
0000120995
-
A class of K-sample tests for comparing the cumulative incidence of a competing risk
-
Gray JR. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
-
(1988)
Ann Stat
, vol.16
, pp. 1141-1154
-
-
Gray, J.R.1
-
16
-
-
84877614360
-
Estimating a timedependent concordance index for survival prediction models with covariate dependent censoring
-
Gerds TA, Kattan MW, Schumacher M, Yu C. Estimating a timedependent concordance index for survival prediction models with covariate dependent censoring. Stat Med 2013;32:2173-84.
-
(2013)
Stat Med
, vol.32
, pp. 2173-2184
-
-
Gerds, T.A.1
Kattan, M.W.2
Schumacher, M.3
Yu, C.4
-
17
-
-
84904070395
-
Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: The value of the pattern of surveillance biopsies
-
Cary KC, Cowan JE, Sanford M, et al. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol 2014;66:337-42.
-
(2014)
Eur Urol
, vol.66
, pp. 337-342
-
-
Cary, K.C.1
Cowan, J.E.2
Sanford, M.3
-
18
-
-
83955162939
-
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program
-
Bul M, van den Bergh RCN, Rannikko A, et al. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol 2012;61:370-7.
-
(2012)
Eur Urol
, vol.61
, pp. 370-377
-
-
Bul, M.1
Van Den Bergh Rcn2
Rannikko, A.3
-
19
-
-
84862018113
-
Chemical castration and anti-androgens induce differential gene expression in prostate cancer
-
Lehmusvaara S, Erkkila T, Urbanucci A, et al. Chemical castration and anti-androgens induce differential gene expression in prostate cancer. J Pathol 2012;227:336-45.
-
(2012)
J Pathol
, vol.227
, pp. 336-345
-
-
Lehmusvaara, S.1
Erkkila, T.2
Urbanucci, A.3
-
20
-
-
84873607610
-
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer
-
Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013;23:159-70.
-
(2013)
Cancer Cell
, vol.23
, pp. 159-170
-
-
Weischenfeldt, J.1
Simon, R.2
Feuerbach, L.3
-
21
-
-
38049123346
-
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
-
Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-63.
-
(2008)
Oncogene
, vol.27
, pp. 253-263
-
-
Attard, G.1
Clark, J.2
Ambroisine, L.3
-
22
-
-
77951723424
-
Molecular sampling of prostate cancer: A dilemma for predicting disease progression
-
Sboner A, Demichelis F, Calza S, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010;3:8.
-
(2010)
BMC Med Genomics
, vol.3
, pp. 8
-
-
Sboner, A.1
Demichelis, F.2
Calza, S.3
-
23
-
-
84890126344
-
Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: Performance of secretion capacity and TMPRSS2:ERG models
-
Whelan C, Kawachi M, Smith DD, et al. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models. J Urol 2014;191:220-6.
-
(2014)
J Urol
, vol.191
, pp. 220-226
-
-
Whelan, C.1
Kawachi, M.2
Smith, D.D.3
-
24
-
-
84866172302
-
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis
-
Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012; 21:1497-509.
-
(2012)
Cancer Epidemiol Biomarkers Prev
, vol.21
, pp. 1497-1509
-
-
Pettersson, A.1
Graff, R.E.2
Bauer, S.R.3
-
26
-
-
78651284982
-
Role of prostate specific antigen andimmediate confirmatory biopsy inpredicting progression during active surveillance for low risk prostate cancer
-
AdamyA, Yee DS, Matsushita K, et al. Role of prostate specific antigen andimmediate confirmatory biopsy inpredicting progression during active surveillance for low risk prostate cancer. J Urol 2011;185: 477-82.
-
(2011)
J Urol
, vol.185
, pp. 477-482
-
-
Adamy, A.1
Yee, D.S.2
Matsushita, K.3
-
27
-
-
84868563896
-
Active surveillance for prostate cancer: A systematic review of the literature
-
Dallera MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-83.
-
(2012)
Eur Urol
, vol.62
, pp. 976-983
-
-
Dallera, M.A.1
Albertsen, P.C.2
Bangma, C.3
-
28
-
-
84902344693
-
PSA doubling time as a progression criterion in an active surveillance programme for patients with localised prostate cancer
-
Thomsen FB, Christensen IJ, Brasso K, Roder MA, Iversen P. PSA doubling time as a progression criterion in an active surveillance programme for patients with localised prostate cancer. BJU Int 2014;113:E98-105.
-
(2014)
BJU Int
, vol.113
, pp. E98-E105
-
-
Thomsen, F.B.1
Christensen, I.J.2
Brasso, K.3
Ma, R.4
Iversen, P.5
-
29
-
-
73949130115
-
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
-
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28: 126-31.
-
(2010)
J Clin Oncol
, vol.28
, pp. 126-131
-
-
Klotz, L.1
Zhang, L.2
Lam, A.3
Nam, R.4
Mamedov, A.5
Loblaw, A.6
-
30
-
-
77956396162
-
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program
-
Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-6.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2810-2816
-
-
Ross, A.E.1
Loeb, S.2
Landis, P.3
|